Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma-4
2011-12-31T18:21:50Z (GMT) by
cells probed with P-radiolabeled oligonucleotide containing the consensus NF-κB sequence. (B) Mean ± 1SD of densitometric values in relative units (RU) from ImageQuant analysis of Phosphor Screens exposed to mini-EMSA from (A). *Coefficient of variation (CV) = 20.9% **CV = 5.9% (C) Chymotrypsin-like activity of the 26S proteasome in 2 patient samples after exposure to increasing doses of bortezomib for 4 hours as assessed by luminescence generated by substrate cleavage (Proteasome-Glo Assay, Promega Corporation, Madison, WI). Results are shown as percent of luminescence relative to a vehicle treated control in a single experiment. (D) Mini-EMSA of anti-CD19 magnetic microbead selected cells from MCL patient samples treated with 20 nM and 100 nM of bortezomib for 4 hours. Z represents a standard composed of 5.0 × 10Z138 cells run with each patient sample as an internal control. The protein extract from this standard was halved, with each half run alongside corresponding halved patient samples, where one half was probed with oligonucleotide containing the NF-κB consensus binding sequence and the other half probed with oligonucleotide containing the Oct-1 consensus binding sequence. (E) NF-κB DNA-binding of MCL patient samples corrected for Oct-1 intensity then normalized to their respective vehicle treated control and finally normalized to Z138 internal control for MCL patient samples processed and analyzed as described in (D). (F) NF-κB DNA-binding of MCL patient 6 after treatment with 1.0 mM POH for 4 hours relative to vehicle treated control, corrected for Oct-1 intensity.
Taken from "Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma"
Molecular Cancer 2008;7():40-40.
Published online 19 May 2008